The first fund, HVP I, is a $3M fund focused on pre-seed and company formation. The second fund, HVP II, is a $35M investment in HBM BioCapital, through which Hatteras is an investment advisor. HVP III is an $83M early- stage fund that invests in breakthrough discoveries that impact human medicine.
With a strategy similar to HVP III, in August 2011 the firm launched HVP IV, a fund that reached its target of $125 million in subscriptions upon final close on January 7, 2013. With HVP IV, Hatteras has formally launched Hatteras Discovery, an allocation of the fund focused on seed-stage companies and projects in the field of human medicine and life sciences.